Abstract
Ivacaftor is a drug that increases the probability of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel remaining open. Information about the efficacy of ivacaftor in patients carrying the rare p.Ser549Arg (S549R) CFTR mutation is sparse. Efficacy of ivacaftor treatment in patients carrying the p.Ser549Arg (S549R) CFTR mutation. Data obtained from CF patients receiving ivacaftor for one year. Eight CF patients, mean age 21±10 years, received ivacaftor. After one year, significant improvement was found in FEV1, increasing from 74% to 88% (p<0.001), FVC, 89% to 101% (p=0.019), and FEF25-75, 59%-76% (p=0.019). Sweat chloride concentration decreased from 116±8mmol/L to 51±17mmol/L (p<0.001), and BMI increased from 20±3 to 22±4 (p=0.003). Glucose tolerance improved in five patients. There was no significant change in bacterial colonization. Ivacaftor therapy resulted in significant clinical improvement in patients carrying the p.Ser549Arg (S549R) CFTR mutation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
